330 related articles for article (PubMed ID: 12017398)
1. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus.
McSorley PT; Bell PM; Jacobsen LV; Kristensen A; Lindholm A
Clin Ther; 2002 Apr; 24(4):530-9. PubMed ID: 12017398
[TBL] [Abstract][Full Text] [Related]
2. Biphasic insulin aspart 30: literature review of adverse events associated with treatment.
Davidson J; Vexiau P; Cucinotta D; Vaz J; Kawamori R
Clin Ther; 2005; 27 Suppl B():S75-88. PubMed ID: 16519039
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of biphasic insulin aspart in patients with type 2 diabetes.
Halimi S; Raskin P; Liebl A; Kawamori R; Fulcher G; Yan G
Clin Ther; 2005; 27 Suppl B():S57-74. PubMed ID: 16519038
[TBL] [Abstract][Full Text] [Related]
4. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients.
Boehm BO; Home PD; Behrend C; Kamp NM; Lindholm A
Diabet Med; 2002 May; 19(5):393-9. PubMed ID: 12027927
[TBL] [Abstract][Full Text] [Related]
5. Comparison of thrice daily 'high' vs. 'medium' premixed insulin aspart with respect to evening and overnight glycaemic control in patients with type 2 diabetes.
Ejskjaer N; Rasmussen M; Kamp N; Lindholm A; Christiansen JS
Diabetes Obes Metab; 2003 Nov; 5(6):438-45. PubMed ID: 14617230
[TBL] [Abstract][Full Text] [Related]
6. An exploratory study of the effect of using high-mix biphasic insulin aspart in people with type 2 diabetes.
Dashora U; Ashwell SG; Home PD
Diabetes Obes Metab; 2009 Jul; 11(7):680-7. PubMed ID: 19527481
[TBL] [Abstract][Full Text] [Related]
7. Postprandial glycemic control with biphasic insulin aspart in patients with type 1 diabetes.
Hermansen K; Vaaler S; Madsbad S; Dalgaard M; Zander M; Begtrup K; Soendergaard K
Metabolism; 2002 Jul; 51(7):896-900. PubMed ID: 12077738
[TBL] [Abstract][Full Text] [Related]
8. Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a meta-analysis.
Davidson JA; Liebl A; Christiansen JS; Fulcher G; Ligthelm RJ; Brown P; Gylvin T; Kawamori R
Clin Ther; 2009 Aug; 31(8):1641-51. PubMed ID: 19808125
[TBL] [Abstract][Full Text] [Related]
9. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes.
Hermansen K; Colombo M; Storgaard H; ØStergaard A; Kølendorf K; Madsbad S
Diabetes Care; 2002 May; 25(5):883-8. PubMed ID: 11978685
[TBL] [Abstract][Full Text] [Related]
10. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
[TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetic and pharmacodynamic properties of different formulations of biphasic insulin aspart: a randomized, glucose clamp, crossover study.
Heise T; Eckers U; Kanc K; Nielsen JN; Nosek L
Diabetes Technol Ther; 2008 Dec; 10(6):479-85. PubMed ID: 19049377
[TBL] [Abstract][Full Text] [Related]
12. [Comparison on the efficacy of biphasic insulin aspart 30 and premixed human insulin 30/70 through continuous glucose monitoring system].
Chen SF; Li H
Zhonghua Liu Xing Bing Xue Za Zhi; 2011 Aug; 32(8):827-9. PubMed ID: 22093477
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan.
Hirao K; Maeda H; Urata S; Takisawa Y; Hirao S; Sasako T; Sasaki T
Clin Ther; 2007 May; 29(5):927-934. PubMed ID: 17697911
[TBL] [Abstract][Full Text] [Related]
14. Biphasic insulin aspart 30/70: pharmacokinetics and pharmacodynamics compared with once-daily biphasic human insulin and Basal-bolus therapy.
Heise T; Heinemann L; Hövelmann U; Brauns B; Nosek L; Haahr HL; Olsen KJ
Diabetes Care; 2009 Aug; 32(8):1431-3. PubMed ID: 19487640
[TBL] [Abstract][Full Text] [Related]
15. Biphasic insulin aspart in type 2 diabetes mellitus: an evidence-based medicine review.
Gough SC; Tibaldi J
Clin Drug Investig; 2007; 27(5):299-324. PubMed ID: 17451279
[TBL] [Abstract][Full Text] [Related]
16. Using continuous glucose monitoring to measure the frequency of low glucose values when using biphasic insulin aspart 30 compared with biphasic human insulin 30: a double-blind crossover study in individuals with type 2 diabetes.
McNally PG; Dean JD; Morris AD; Wilkinson PD; Compion G; Heller SR
Diabetes Care; 2007 May; 30(5):1044-8. PubMed ID: 17277042
[TBL] [Abstract][Full Text] [Related]
17. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus.
Niskanen L; Jensen LE; Råstam J; Nygaard-Pedersen L; Erichsen K; Vora JP
Clin Ther; 2004 Apr; 26(4):531-40. PubMed ID: 15189750
[TBL] [Abstract][Full Text] [Related]
18. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study).
Garber AJ; Wahlen J; Wahl T; Bressler P; Braceras R; Allen E; Jain R
Diabetes Obes Metab; 2006 Jan; 8(1):58-66. PubMed ID: 16367883
[TBL] [Abstract][Full Text] [Related]
19. Clinical effectiveness of biphasic insulin aspart 30:70 versus biphasic human insulin 30 in UK general clinical practice: a retrospective database study.
Morgan CL; Evans M; Toft AD; Jenkins-Jones S; Poole CD; Currie CJ
Clin Ther; 2011 Jan; 33(1):27-35. PubMed ID: 21397771
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes.
Luzio S; Dunseath G; Peter R; Pauvaday V; Owens DR
Diabetologia; 2006 Jun; 49(6):1163-8. PubMed ID: 16596358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
